# The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met

Source: https://onco.cc/trials/nct06959589/  
OnCo record `nct06959589` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.

## Summary

The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06959589 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 50 participants, started 2025-05-22 and due to reach its primary completion in 2027-05-31. Interventions recorded: IBI351, cetuximab β combined with FOLFIRI. Conditions listed: Colorectal Cancer Metastatic; KRAS G12C Mutation. Primary outcome: ORR. Colorectal eligibility wording from the registry: "The patient must have histologically and/or cytologically confirmed metastatic colorectal cancer (stage IV) 3". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: cruciall
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06959589
- Phase: 2
- Setting: An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT06959589: https://clinicaltrials.gov/study/NCT06959589

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06959589.json